| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.1 | 0.001 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.002 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | -0.098 | 0.002 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.41 | 0.002 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.088 | 0.003 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.094 | 0.004 |